Overview

Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis

Status:
Completed

Trial end date:
2011-05-01

Target enrollment:

Participant gender:

Summary

Evaluate the safety, tolerability and pharmacokinetics of AIN457 when administered as treatment of moderate to severe ankylosing spondylitis (AS).

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals